Jane Lowe Meisel News Today

Jane Lowe Meisel, MD, presents data from a retrospective study investigating patient characteristics, treatment patterns, and clinical outcomes for tucatinib-based treatment in the real-world setting both overall and following fam-trastuzumab deruxtecan (T-DXd).

Jane Lowe Meisel, MD, discusses previously reported data from the ELAINE-1 and ELAINE-2 trials, their significance within the ESR1-mutant, ER-positive, HER2-negative breast cancer treatment paradigm, and the purpose of the ongoing ELAINE-3 trial.

Practice-changing therapy for HER2-low breast cancer, potential for some women to skip surgery

JScreen’s CancerGEN screening program is a lifesaver.

“To prevent cancer on a wide scale, accessible genetic testing is key,” says Jane Lowe Meisel, MD, Associate Professor of Hematology and Medical Oncology at Emory University School of Medicine. “Cancer genetic testing makes prevention and early detection possible.”

CHICAGO — Trastuzumab deruxtecan significantly extended PFS and OS among patients with HER2-low metastatic breast cancer, regardless of hormone receptor status, compared with standard of care therapy.Results of the phase 3 DESTINY-Breast04 trial, presented at ASCO Annual Meeting and published simultaneously in The New England Journal of Medicine, additionally showed fam-trastuzumab

Sacituzumab govitecan (Trodelvy) beat chemotherapy in patients with heavily pretreated endocrine resistant HR+/HER2- advanced breast cancer, who represent a great clinical unmet need, says expert.

Breast cancer patients with low levels of HER2 expression, previously considered untreatable with HER2-targeted therapies, had improved progression-free survival with trastuzumab deruxtecan (Enhertu).

BioPharma

The antibody-drug conjugate stretched out time to progression in a Phase III trial of pretreated patients with advanced hormone receptor-positive, HER2-negative breast cancers.